Abstract 1695P
Background
Electronic patient reported outcomes (ePROs) have been shown to improve the quality of life and survival, and reduce the number of unscheduled health care visits in chemotherapy treated patients (pts) with advanced cancers. We hypothesized that ePRO follow-up could improve symptom management, streamline patient flow, and reduce the use of additional healthcare resources among colorectal cancer (CRC) pts treated with oxaliplatin-based chemotherapy in adjuvant setting.
Methods
CRC pts (n=35) who were planned to receive oxaliplatin-based chemotherapy as an adjuvant treatment were recruited (7/2019-1/2021) to a multicenter prospective clinical trial (NCT04081558) investigating a novel KaikuHealth ePRO tool consisting of a weekly symptom questionnaire integrated to an urgency algorithm and laboratory value interface. To assess the adherence to follow-up, pts and healthcare professionals (HCP) perspectives were collected via questionnaires. The efficiency end-points were compared to a sequentially collected (1-7/2017) retrospective cohort from the same institutes (n=25).
Results
The feasibility of ePRO follow-up was found to be good with 98% of the pts suggesting that the use of the platform was easy and 86% felt that it improved their cancer care. The HCPs valued the easy use and logical workflow as the most important features. Compared to historical controls, the ePRO follow-up was able to reduce the number of phone calls to the pts before a new chemotherapy cycle by 57%. Furthermore, ePRO follow-up detected evolving peripheral neuropathy earlier in a univariate and multivariate analysis (HR 4.33, CI 1.60-11.74) including the baseline dose intensity. There were tendencies for more frequent dose delays and outpatient visits among the ePRO pts but this was not associated with chemotherapy dose reductions or treatment duration.
Conclusions
The results suggest that ePRO follow-up of CRC pts treated in adjuvant setting is feasible from the perspective of pts and HCPs. Furthermore, ePRO follow-up detecs evolving neuropathy earlier enhancing symptom management without compromising chemotherapy dose intensity, thus, improving the quality in cancer care.
Clinical trial identification
NCT04081558.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche.
Disclosure
S.M.E. Iivanainen: Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal and Institutional, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pierre-Robert; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal and Institutional, Research Grant: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Takeda. R. Arokoski: Financial Interests, Personal, Full or part-time Employment: Kaiku Health Oy. J. Ekstrom: Financial Interests, Personal, Full or part-time Employment: Kaiku Health Oy. S. Mentu: Financial Interests, Personal, Full or part-time Employment: Kaiku Health Oy. H. Virtanen: Financial Interests, Personal, Full or part-time Employment: Kaiku Health Oy. V. Kataja: Financial Interests, Personal, Full or part-time Employment: Kaiku Health Oy. J.P. Koivunen: Financial Interests, Personal, Advisory Board: Merck Sharp Dome; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Full or part-time Employment: Faron Pharmaceuticals; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.